Composition containing dihomo-gamma-linolenic acid (DGLA) as the active ingredient

A composition and drug technology, applied in the fields of mast cell number increase inhibitors and eosinophil infiltration inhibitors, can solve problems affecting drug efficacy, safety or use methods, and skin inflammation deterioration

Active Publication Date: 2013-05-15
SUNTORY HLDG LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0036] This shows that these medicines are useful for the prevention and treatment of various diseases related to mast cells, such as allergic diseases. On the other hand, there are actually problems with their safety or use methods.
When using steroid external preparations, side effects such as red tides during use, skin atrophy, and rebound phenomenon that aggravates skin inflammation after discontinuation of administration may occur; The site of application and the barrier function of the skin greatly affect the efficacy of the drug (Journal of the Japanese Society of Dermatology, Furue Yoshitaka, 2004, 114, p.135~)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing dihomo-gamma-linolenic acid (DGLA) as the active ingredient
  • Composition containing dihomo-gamma-linolenic acid (DGLA) as the active ingredient
  • Composition containing dihomo-gamma-linolenic acid (DGLA) as the active ingredient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0130] As described above, since the ingestion of DGLA is expected to be useful for the prevention or treatment of atopic dermatitis, SUNTGD, a triglyceride of DGLA oil, was used in experimental animals to study its usefulness. Triglyceride SUNTGD is prepared according to the method described in Japanese Patent No. 3354581, and contains DGLA as a main constituent fatty acid. This time, NC / Nga mice were used as an animal model of atopic dermatitis. This animal model was confirmed as one of the most useful animal models of atopic dermatitis at present, and it was proved that it is actually in the clinical field of atopic treatment. The steroid topical agents and immunosuppressants used are also effective in this animal model, so they are widely used in screening tests for drugs for the treatment of atopic dermatitis.

[0131] Under the usual breeding environment, the animal naturally develops dermatitis around 8 weeks after birth, and its inflammatory condition becomes more seve...

Embodiment 2

[0156] In order to find out the relationship between the amount of DGLA taken orally and the level of DGLA in the body, the oral intake of DGLA was analyzed by surveying diet, and the amount of DGLA in serum phospholipids was measured after blood collection. The subjects were 11 healthy men aged 60 to 70, who made a daily record of their meal content and food raw materials for a week, and calculated the intake of meat, eggs, fish and shellfish food raw materials known to contain DGLA based on the records. According to the "Four Sets Japanese Food Standard Composition Table, Japanese Food Fat-soluble Component Table (1990)", the DGLA content of each food raw material can be calculated, and the daily DGLA intake per person can be calculated using this content. Calculate the average daily DGLA intake per person based on the DGLA intake within one week.

[0157]On the other hand, blood was drawn on the day after the last day recorded in the diary, and the obtained serum phospholip...

Embodiment 3

[0161] We know that the skin is damaged by sunlight in skin diseases, especially ultraviolet rays with a wavelength of 290nm to 320nm classified as UV-B are considered to cause acute skin inflammation (sunburn), pigmentation, and sun exposure. (suntan), one of the biggest causes of skin cancer etc. This time, in order to further study the possibility of the effect of DGLA on skin function, guinea pigs with acute skin inflammation induced by UV-B were used as animal models to evaluate the effect of DGLA on acute skin inflammation. This animal model is one of the most useful animal models for drug efficacy screening in the development of pharmaceuticals expected to have anti-inflammatory effects.

[0162] In this test, male Hartley guinea pigs were prepared, divided into a control diet group and a DGLA diet group, and allowed to ingest each diet continuously from the age of 5 weeks to the age of 7 weeks at the end of the experiment. The composition of the DGLA diet used this ti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

It is intended to provide a composition such as a food or a drug which contains dihomo--linolenic acid (DGLA) and has a preventive or therapeutic effect on a skin disease; a composition such as a food or a drug which contains dihomo--linolenic acid (DGLA) and has a preventive or therapeutic effect on a skin disease; and a composition which contains dihomo--linolenic acid (DGLA) and is efficaciousin preventing or treating a disease relating to an increase in the mast cell count.

Description

technical field [0001] The present invention relates to a food ingredient having a preventive or therapeutic effect on various skin diseases such as allergic dermatitis such as atopic dermatitis and contact dermatitis, eczema, and skin damage caused by ultraviolet rays, or a food composition containing the same , specifically pertaining to the most appropriate dosage provided in order to maximize the effect of the ingredient. [0002] The present invention also relates to a food ingredient having a preventive or therapeutic effect on various diseases closely related to eosinophil infiltration or eosinophil count increase, such as skin disease, respiratory system disease, and digestive system disease, or a food containing the food ingredient Compositions or pharmaceutical compositions, especially related to inhibitors of eosinophil infiltration. [0003] Furthermore, the present invention relates to a food ingredient having a preventive or therapeutic effect on various disease...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/202A61K31/232A61K31/661A61K9/20A61K9/48A61P17/00A61P37/08A61P11/00A61P11/06A61P1/04A61P35/00A23L1/30
Inventor 立石法史河岛洋
Owner SUNTORY HLDG LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products